Dr. Sundeep Kumar Upadhyaya

Professional Summary

Dr. Sundeep Kumar Upadhyaya is a highly skilled and experienced rheumatologist based in South Delhi, India, with over 30 years of dedicated practice in the field of rheumatology and immunology. Holding the prestigious qualifications of MBBS, MD, and DM, Dr. Upadhyaya integrates his extensive knowledge with a compassionate approach to patient care. His expertise encompasses a broad range of rheumatological conditions, enabling him to accurately diagnose and effectively treat disorders affecting the joints, muscles, and bones. Dr. Upadhyaya is committed to improving the quality of life for his patients through comprehensive treatment plans and ongoing management strategies. Fluent in multiple languages including English, Hindi, Bhojpuri, Marathi, Gujarati, Bengali, Kashmiri, and Malayalam, he is adept at communicating with a diverse patient demographic — making him an excellent choice for international patients seeking specialized rheumatological care in India. His reputation as a reliable and empathetic physician has earned him a loyal patient following in the rheumatology community.

Specializations

- Rheumatology

Procedures & Expertise

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Sjögren's Syndrome
- Psoriatic Arthritis
- Systemic Sclerosis (Scleroderma)
- Mixed Connective Tissue Disease
- Vasculitis
- Systemic Lupus Erythematosus
- Osteoporosis (Severe / Refractory)
- Refractory Gout

Education & Qualifications

- DM — Rheumatology & Immunology
- MD — Medicine, University Allahabad (1986–1996, PG Training)
- MBBS

Hospital Affiliations

- Apollo Hospitals, Delhi (Indraprastha Apollo Hospitals, New Delhi)
- Apollo Hospitals, Noida

Memberships

- Member, IRA (Indian Rheumatology Association)
- Member, API (Association of Physicians of India)
- Member, DRA (Delhi Rheumatology Association)

Research & Publications

- Rheumatic manifestations in diabetes mellitus patients — Authors: Bhowmik, Meghnathi, Sundeep K Upadhyaya. Apollo Medicine, June 2013.
- Antibodies to Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis and Spondyloarthritis — Open Journal of Rheumatology and Autoimmune Diseases, 2014.
- Primary Investigator for Clinical Research in Rheumatoid Arthritis (Jhonson & Jhonson Simponi Phase IV Trial) for multiple pharmaceutical partners including Roche, Eli Lilly, and others.
- Research on the construct validity of SDAI, CDAI, and HAQ-DI compared to DAS 28 in Rheumatoid Arthritis patients (DNB Thesis project — Chief Guide).